Clinical Trial Update: The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GLP-1(7-36) amide for glycemic control in critically ill patients was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoglycemia

Drugs mentioned

• Glucagon-like peptide-1(7-36) amide (GLP-1(7-36) amide)

Snippet

Sponsor: Johns Hopkins University | Conditions: Critically Ill, Hypoglycemia | Phase 2 | Status: TERMINATED | Results posted: 2017-07-02